Loading...
•
Sep 30, 2021
Reviva Q3 2021 Earnings Report
Reported third quarter 2021 financial results and recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $2.28 million for the third quarter of 2021. As of September 30, 2021, the company's cash totaled $33.5 million.
Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end.
Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophrenia expected to begin by year-end.
Regulatory submissions to the FDA for initiating Phase 2 studies in PAH and IPF now expected by the end of Q1 2022.
Cash totaled $33.5 million as of September 30, 2021.
Reviva
Reviva
Forward Guidance
Based on the current operating plan and financial resources, the Company’s cash and cash equivalents at the quarter ended September 30, 2021 will be sufficient to cover general operating expenses through the fourth quarter of 2022.